Bile acid receptors as targets for drug development (original) (raw)

• Hagey, L. R. et al. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J. Lipid Res. 34, 1911–1917 (1993).
  CAS PubMed Google Scholar
• Maton, P. N., Murphy, G. M. & Dowling, R. H. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action. Lancet 2, 1297–1301 (1977).
  CAS PubMed Google Scholar
• Poupon, R. et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1, 834–836 (1987).
  CAS PubMed Google Scholar
• Salen, G., Meriwether, T. W. & Nicolau, G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem. Med. 14, 57–74 (1975).
  CAS PubMed Google Scholar
• Hench, P. S. Effect of jaundice on rheumatoid arthritis. Br. Med. J. 2, 394–398 (1938).
  CAS PubMed PubMed Central Google Scholar
• Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174 (2003).
  CAS PubMed Google Scholar
• Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259 (2006).
  CAS PubMed Google Scholar
• Dawson, P. A., Lan, T. & Rao, A. Bile acid transporters. J. Lipid Res. 50, 2340–2357 (2009).
  CAS PubMed PubMed Central Google Scholar
• Hofmann, A. F. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 6, 15–27 (2007).
  CAS PubMed Google Scholar
• Borgstrom, B., Dahlqvist, A., Lundh, G. & Sjovall, J. Studies of intestinal digestion and absorption in the human. J. Clin. Invest. 36, 1521–1536 (1957).
  CAS PubMed PubMed Central Google Scholar
• Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687–693 (1995).
  CAS PubMed Google Scholar
• Seol, W., Choi, H. S. & Moore, D. D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9, 72–85 (1995).
  CAS PubMed Google Scholar
• Shefer, S., Hauser, S., Bekersky, I. & Mosbach, E. H. Feedback regulation of bile acid biosynthesis in the rat. J. Lipid Res. 10, 646–655 (1969).
  CAS PubMed Google Scholar
• Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517–526 (2000).
  CAS PubMed Google Scholar
• Seol, W., Choi, H. S. & Moore, D. D. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272, 1336–1339 (1996).
  CAS PubMed Google Scholar
• Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2, 217–225 (2005).
  CAS PubMed Google Scholar
• Houten, S. M., Watanabe, M. & Auwerx, J. Endocrine functions of bile acids. EMBO J. 25, 1419–1425 (2006).
  CAS PubMed PubMed Central Google Scholar
• Huang, W. et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312, 233–236 (2006).
  CAS PubMed Google Scholar
• Inagaki, T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. USA 103, 3920–3925 (2006).
  CAS PubMed PubMed Central Google Scholar
• Alemi, F. et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145–154 (2013).
  CAS PubMed Google Scholar
• Higuchi, H., Grambihler, A., Canbay, A., Bronk, S. F. & Gores, G. J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N.-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 279, 51–60 (2004).
  CAS PubMed Google Scholar
• Allen, K., Jaeschke, H. & Copple, B. L. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am. J. Pathol. 178, 175–186 (2011).
  CAS PubMed PubMed Central Google Scholar
• Baes, M. et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell Biol. 14, 1544–1552 (1994).
  CAS PubMed PubMed Central Google Scholar
• Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313–1316 (2002).
  CAS PubMed Google Scholar
• Choi, H. S. et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272, 23565–23571 (1997).
  CAS PubMed Google Scholar
• Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714–719 (2002).
  CAS PubMed Google Scholar
• Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435–9440 (2003).
  CAS PubMed Google Scholar
• Otte, K. et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell Biol. 23, 864–872 (2003).
  CAS PubMed PubMed Central Google Scholar
• Zhang, Y., Kast-Woelbern, H. R. & Edwards, P. A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278, 104–110 (2003).
  CAS PubMed Google Scholar
• Bookout, A. L. et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789–799 (2006).
  CAS PubMed PubMed Central Google Scholar
• Li, Z., Kruijt, J. K., van der Sluis, R. J., Van Berkel, T. J. & Hoekstra, M. Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells. Physiol. Genomics 45, 268–275 (2013).
  CAS PubMed Google Scholar
• Fickert, P. et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol. 175, 2392–2405 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101, 3668–3673 (2004).
  CAS PubMed PubMed Central Google Scholar
• Lee, H. et al. FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine. J. Lipid Res. 47, 201–214 (2006).
  CAS PubMed Google Scholar
• Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039–11049 (2006).
  CAS PubMed Google Scholar
• Jiang, T. et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485–2493 (2007).
  CAS PubMed Google Scholar
• Abel, U. et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 20, 4911–4917 (2010).
  CAS PubMed Google Scholar
• Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell. Metab. 17, 225–235 (2013).
  CAS PubMed Google Scholar
• Beraza, N. et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 60, 387–396 (2011).
  CAS PubMed Google Scholar
• Gardmo, C., Tamburro, A., Modica, S. & Moschetta, A. Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim. Biophys. Acta 1812, 836–841 (2011).
  CAS PubMed PubMed Central Google Scholar
• Jung, D. & Kullak-Ublick, G. A. Hepatocyte nuclear factor 1 α: a key mediator of the effect of bile acids on gene expression. Hepatology 37, 622–631 (2003).
  CAS PubMed Google Scholar
• Jung, D., Mangelsdorf, D. J. & Meyer, U. A. Pregnane X receptor is a target of farnesoid X receptor. J. Biol. Chem. 281, 19081–19091 (2006).
  CAS PubMed Google Scholar
• Inoue, J. et al. PPARα gene expression is up-regulated by LXR and PXR activators in the small intestine. Biochem. Biophys. Res. Commun. 371, 675–678 (2008).
  CAS PubMed Google Scholar
• Renga, B. et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim. Biophys. Acta 1809, 157–165 (2011).
  CAS PubMed Google Scholar
• Beilke, L. D. et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab. Dispos. 37, 1035–1045 (2009).
  CAS PubMed PubMed Central Google Scholar
• Claudel, T., Staels, B. & Kuipers, F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25, 2020–2030 (2005).
  CAS PubMed Google Scholar
• Wang, Y. D., Chen, W. D., Moore, D. D. & Huang, W. FXR: a metabolic regulator and cell protector. Cell Res. 18, 1087–1095 (2008).
  CAS PubMed Google Scholar
• Pircher, P. C. et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278, 27703–27711 (2003).
  CAS PubMed Google Scholar
• Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. & Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857–28865 (2001).
  CAS PubMed Google Scholar
• Boyer, J. L. et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1124–G1130 (2006).
  CAS PubMed Google Scholar
• Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497–1512 (2004).
  CAS PubMed Google Scholar
• Kim, I. et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940–946 (2007).
  CAS PubMed Google Scholar
• Deuschle, U. et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS ONE 7, e43044 (2012).
  CAS PubMed PubMed Central Google Scholar
• Jiang, Y. et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology 57, 1098–1106 (2013).
  CAS PubMed Google Scholar
• Wistuba, W., Gnewuch, C., Liebisch, G., Schmitz, G. & Langmann, T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol. 13, 4230–4235 (2007).
  CAS PubMed PubMed Central Google Scholar
• Schmidt, D. R. et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486–14494 (2010).
  CAS PubMed PubMed Central Google Scholar
• Schreuder, T. C. et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am. J. Physiol. Gastrointest Liver Physiol. 298, G440–G445 (2010).
  CAS PubMed Google Scholar
• Triantis, V., Saeland, E., Bijl, N., Oude-Elferink, R. P. & Jansen, P. L. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology 52, 656–666 (2010).
  CAS PubMed Google Scholar
• Wu, X. et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282, 29069–29072 (2007).
  CAS PubMed Google Scholar
• Kir, S., Zhang, Y., Gerard, R. D., Kliewer, S. A. & Mangelsdorf, D. J. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J. Biol. Chem. 287, 41334–41341 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664–2672 (2007).
  CAS PubMed Google Scholar
• Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell. Metab. 13, 729–738 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621–1624 (2011).
  CAS PubMed PubMed Central Google Scholar
• Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K. & Yamazoe, Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol. Pharm. Bull. 34, 1885–1889 (2011).
  CAS PubMed Google Scholar
• Choi, M. et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12, 1253–1255 (2006).
  CAS PubMed Google Scholar
• Drafahl, K. A., McAndrew, C. W., Meyer, A. N., Haas, M. & Donoghue, D. J. The receptor tyrosine kinase FGFR4 negatively regulates NF-κB signaling. PLoS ONE 5, e14412 (2010).
  CAS PubMed PubMed Central Google Scholar
• Uriarte, I. et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 62, 899–910 (2013).
  CAS PubMed Google Scholar
• Zweers, S. J. et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 55, 575–583 (2012).
  CAS PubMed Google Scholar
• Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295–2307 (2002).
  CAS PubMed PubMed Central Google Scholar
• Lin, B. C. & Desnoyers, L. R. FGF19 and cancer. Adv. Exp. Med. Biol. 728, 183–194 (2012).
  CAS PubMed Google Scholar
• Wu, X. et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl Acad. Sci. USA 107, 14158–14163 (2010).
  CAS PubMed PubMed Central Google Scholar
• Keitel, V. et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50, 861–870 (2009).
  CAS PubMed Google Scholar
• Keitel, V. et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58, 1794–1805 (2010).
  PubMed Google Scholar
• Keitel, V. et al. The G.-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45, 695–704 (2007).
  CAS PubMed Google Scholar
• Sato, H. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 362, 793–798 (2007).
  CAS PubMed Google Scholar
• Sato, H. et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831–1841 (2008).
  CAS PubMed Google Scholar
• Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J. & Schoonjans, K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 54, 1263–1272 (2011).
  CAS PubMed Google Scholar
• Pols, T. W. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell. Metab. 14, 747–757 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wang, Y. D., Chen, W. D., Yu, D., Forman, B. M. & Huang, W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54, 1421–1432 (2011).
  CAS PubMed Google Scholar
• Katsuma, S., Hirasawa, A. & Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386–390 (2005).
  CAS PubMed Google Scholar
• Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell. Metab. 10, 167–177 (2009).
  CAS PubMed PubMed Central Google Scholar
• Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484–489 (2006).
  CAS PubMed Google Scholar
• Jansen, P. L. et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 29, 48–51 (2011).
  PubMed Google Scholar
• Li, T. et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 25, 1066–1071 (2011).
  CAS PubMed PubMed Central Google Scholar
• Beuers, U. et al. The biliary HCO3− umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52, 1489–1496 (2010).
  CAS PubMed Google Scholar
• Zhang, H. et al. Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch. Biochem. Biophys. 368, 14–22 (1999).
  CAS PubMed Google Scholar
• Kliewer, S. A. et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73–82 (1998).
  CAS PubMed Google Scholar
• Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016–1023 (1998).
  CAS PubMed PubMed Central Google Scholar
• Bertilsson, G. et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 95, 12208–12213 (1998).
  CAS PubMed PubMed Central Google Scholar
• Lamba, V. et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 199, 251–265 (2004).
  CAS PubMed Google Scholar
• Vogel, S. M. et al. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc. Natl Acad. Sci. USA 109, 16906–16910 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wang, Y. M., Ong, S. S., Chai, S. C. & Chen, T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8, 803–817 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kast, H. R. et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908–2915 (2002).
  CAS PubMed Google Scholar
• Ihunnah, C. A., Jiang, M. & Xie, W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim. Biophys. Acta 1812, 956–963 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wallace, K. et al. The PXR is a drug target for chronic inflammatory liver disease. J. Steroid Biochem. Mol. Biol. 120, 137–148 (2010).
  CAS PubMed PubMed Central Google Scholar
• Li, T. & Chiang, J. Y. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 α-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G74–G84 (2005).
  CAS PubMed Google Scholar
• Cheng, J., Shah, Y. M. & Gonzalez, F. J. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33, 323–330 (2012).
  CAS PubMed PubMed Central Google Scholar
• Zhou, J. et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology 134, 556–567 (2008).
  CAS PubMed Google Scholar
• Jonker, J. W., Liddle, C. & Downes, M. FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 130, 147–158 (2012).
  CAS PubMed Google Scholar
• Norman, A. W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542–5548 (2006).
  CAS PubMed Google Scholar
• Han, S. & Chiang, J. Y. Mechanism of vitamin D receptor inhibition of cholesterol 7α-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos. 37, 469–478 (2009).
  CAS PubMed Google Scholar
• Adachi, R. et al. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol. Endocrinol. 18, 43–52 (2004).
  CAS PubMed Google Scholar
• Huhtakangas, J. A., Olivera, C. J., Bishop, J. E., Zanello, L. P. & Norman, A. W. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-vitamin D3 in vivo and in vitro. Mol. Endocrinol. 18, 2660–2671 (2004).
  CAS PubMed Google Scholar
• Han, S., Li, T., Ellis, E., Strom, S. & Chiang, J. Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol. 24, 1151–1164 (2010).
  CAS PubMed PubMed Central Google Scholar
• D'Aldebert, E. et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136, 1435–1443 (2009).
  CAS PubMed Google Scholar
• Saini, S. P. et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65, 292–300 (2004).
  CAS PubMed Google Scholar
• Chang, T. K. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 11, 590–601 (2009).
  CAS PubMed PubMed Central Google Scholar
• Moore, L. B. et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 16, 977–986 (2002).
  CAS PubMed Google Scholar
• Miao, J., Fang, S., Bae, Y. & Kemper, J. K. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1α. J. Biol. Chem. 281, 14537–14546 (2006).
  CAS PubMed Google Scholar
• Uppal, H. et al. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41, 168–176 (2005).
  CAS PubMed Google Scholar
• Pellicciari, R. et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569–3572 (2002).
  CAS PubMed Google Scholar
• Pellicciari, R. et al. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958–7961 (2009).
  CAS PubMed Google Scholar
• Rizzo, G. et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78, 617–630 (2010).
  CAS PubMed PubMed Central Google Scholar
• Baghdasaryan, A. et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− (Abcb4 −/−) mouse cholangiopathy model by promoting biliary HCO3− output. Hepatology 54, 1303–1312 (2011).
  CAS PubMed Google Scholar
• Adorini, L., Pruzanski, M. & Shapiro, D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 17, 988–997 (2012).
  CAS PubMed Google Scholar
• Hartman, H. B. et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR −/− and apoE −/− mice. J. Lipid Res. 50, 1090–1100 (2009).
  CAS PubMed PubMed Central Google Scholar
• Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272–H281 (2009).
  CAS PubMed Google Scholar
• Urizar, N. L. et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296, 1703–1706 (2002).
  CAS PubMed Google Scholar
• Zhang, Y. et al. FXR deficiency causes reduced atherosclerosis in Ldlr −/− mice. Arterioscler Thromb. Vasc Biol. 26, 2316–2321 (2006).
  CAS PubMed Google Scholar
• Guo, G. L. et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761, 1401–1409 (2006).
  CAS PubMed PubMed Central Google Scholar
• Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell. Metab. 17, 49–60 (2013).
  CAS PubMed PubMed Central Google Scholar
• Marinozzi, M. et al. Pyrazole[3,4-_e_][1 4]thiazepin-7-one derivatives as a novel class of farnesoid X receptor (FXR) agonists. Bioorg. Med. Chem. 20, 3429–3445 (2012).
  CAS PubMed Google Scholar
• Herbert, M. R. et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg. Med. Chem. Lett. 20, 5718–5721 (2010).
  CAS PubMed Google Scholar
• Sakamoto, S. et al. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6, 7,8-trimethoxy-2-naphthoat e (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 322, 610–618 (2007).
  CAS PubMed Google Scholar
• Kobayashi, M. et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56, 239–247 (2007).
  CAS PubMed Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51, 237–267 (2009).
• Beuers, U. et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33, 1206–1216 (2001).
  CAS PubMed Google Scholar
• Garcia-Marin, J. J., Dumont, M., Corbic, M., de Couet, G. & Erlinger, S. Effect of acid-base balance and acetazolamide on ursodeoxycholate-induced biliary bicarbonate secretion. Am. J. Physiol. 248, G20–G27 (1985).
  CAS PubMed Google Scholar
• Kurz, A. K., Graf, D., Schmitt, M., Vom Dahl, S. & Haussinger, D. Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 121, 407–419 (2001).
  CAS PubMed Google Scholar
• Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R. & Haussinger, D. α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 57, 1117–1129 (2013).
  CAS PubMed Google Scholar
• Bouscarel, B., Fromm, H. & Nussbaum, R. Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes. Am. J. Physiol. 264, G243–G251 (1993).
  CAS PubMed Google Scholar
• Wong, M. H., Oelkers, P., Craddock, A. L. & Dawson, P. A. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J. Biol. Chem. 269, 1340–1347 (1994).
  CAS PubMed Google Scholar
• Mekjian, H. S., Phillips, S. F. & Hofmann, A. F. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J. Clin. Invest. 50, 1569–1577 (1971).
  CAS PubMed Google Scholar
• Harach, T. et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2, 430 (2012).
  PubMed PubMed Central Google Scholar
• Chen, L. et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am. J. Physiol. Endocrinol. Metab. 302, E68–E76 (2012).
  CAS PubMed Google Scholar
• Bhat, B. G. et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE −/− mice by SC-435. J. Lipid Res. 44, 1614–1621 (2003).
  CAS PubMed Google Scholar
• Li, H. et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 α-hydroxylase. Metabolism 53, 927–932 (2004).
  CAS PubMed Google Scholar
• Insull, W. Jr et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. 76, 971–982 (2001).
  CAS PubMed Google Scholar
• Hansen, M. et al. Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open 2, e001803 (2012).
  PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2013).
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228–1235 (2009).
  CAS PubMed Google Scholar
• Fickert, P. et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261–274 (2004).
  CAS PubMed Google Scholar
• Fiorucci, S. et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev. Med. Chem. 11, 753–762 (2011).
  CAS PubMed Google Scholar
• Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1008–1018 (2010).
  CAS PubMed Google Scholar
• Kremer, A. E. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56, 1391–1400 (2012).
  CAS PubMed Google Scholar
• Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513–1530 (2013).
  CAS PubMed PubMed Central Google Scholar
• Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463–472 (2011).
  CAS PubMed Google Scholar
• Terjung, B. et al. p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59, 808–816 (2010).
  CAS PubMed Google Scholar
• Wong, B. S. et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin. Gastroenterol. Hepatol. 10, 1009–1015 e3 (2012).
  CAS PubMed PubMed Central Google Scholar
• Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2013.05.042.
• Wang, X. X. et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59, 2916–2927 (2010).
  CAS PubMed PubMed Central Google Scholar
• Peterli, R. et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann. Surg. 250, 234–241 (2009).
  PubMed Google Scholar
• van Dijk, R., Kremer, A. F., Enemuo, V., Jansen, P. L., Beuers, U. Clinical and molecular aspects of rifampicin-mediated attenuation of severe persistent hepatocellular secretory failure. Hepatology 56, 549A (2012).
  Google Scholar
• Ohkubo, H., Okuda, K. & Iida, S. Effects of corticosteroids on bilirubin metabolism in patients with Gilbert's syndrome. Hepatology 1, 168–172 (1981).
  CAS PubMed Google Scholar
• Arias, I. M., Gartner, L. M., Cohen, M., Ezzer, J. B. & Levi, A. J. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am. J. Med. 47, 395–409 (1969).
  CAS PubMed Google Scholar
• Ellis, E. et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J. Hepatol. 44, 243–245 (2006).
  PubMed Google Scholar
• Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 (1999).
  CAS PubMed Google Scholar
• Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079–1092 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hambruch, E. et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor(−/−) mice. J. Pharmacol. Exp. Ther. 343, 556–567 (2012).
  CAS PubMed Google Scholar
• Flatt, B. et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52, 904–907 (2009).
  CAS PubMed Google Scholar
• Soisson, S. M. et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl Acad. Sci. USA 105, 5337–5342 (2008).
  CAS PubMed PubMed Central Google Scholar
• Bass, J. Y. et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg. Med. Chem. Lett. 21, 1206–1213 (2011).
  CAS PubMed Google Scholar
• Chen, W. D. et al. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 51, 953–962 (2010).
  CAS PubMed Google Scholar
• Hollman, D. A., Milona, A., van Erpecum, K. J. & van Mil, S. W. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta 1821, 1443–1452 (2012).
  CAS PubMed Google Scholar
• Staudinger, J. L. et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98, 3369–3374 (2001).
  CAS PubMed PubMed Central Google Scholar
• Jones, S. A. et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14, 27–39 (2000).
  CAS PubMed Google Scholar
• Moore, L. B. et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA 97, 7500–7502 (2000).
  CAS PubMed PubMed Central Google Scholar
• Ogura, M. et al. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 328, 564–570 (2009).
  CAS PubMed Google Scholar
• Ma, Y. et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest. 116, 892–904 (2006).
  CAS PubMed PubMed Central Google Scholar
• Maglich, J. M. et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 62, 638–646 (2002).
  CAS PubMed Google Scholar
• Gao, J. & Xie, W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol. Sci. 33, 552–558 (2012).
  CAS PubMed PubMed Central Google Scholar